ClinicalTrials.gg
CompletedNCT06006546Updated Nov 6, 2026

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

A Phase 1 interventional study of 426c.Mod.Core-C4b and Adjuvant 3M-052-AF+Alum in Chronic HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 7 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) — 10 open to participants now, 15 under way, 1 of them phase 3. HIV Infections · National Institute of Allergy and Infectious Diseases (NIAID).

Enrollment
598th of 883
35 · median 59
Started
2024
with 5 others
Phase 1
365 of 1,034
4 open now
Registered
1,025th of 1,034
by date

Among the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 598th largest by enrollment of the 883 interventional ones that give a count, is one of 6 that started in 2024, is one of 365 in phase 1, and was the 1,025th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,034 studies in HIV Infections by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).

Read the detailed description

The aim of this study is to combine the ability of germline (GL)-targeting HIV-1 Envelope protein (Env)-derived immunogens to activate naïve B cells that express the unmutated GL forms of VRC01-class broadly neutralizing antibodies (bnAbs) with the booster capabilities of viral Envs that are expected to circulate in persons living with chronic HIV. The goals are: 1) to elicit VRC01-class GL and intermediate stage antibody responses in PLWH; 2) to identify the viral Envs that guided the maturation of the GL-VRC01 responses elicited by the GL-targeting Env immunogen; 3) during the time when viremia is detectable, the investigator will assess the stage of maturation of these VRC01 antibodies and if they affect viral replication; and 4) investigate how the virus may evolve to escape the activity of these antibodies.

03

Conditions studied

  • Chronic HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to complete the process, including an Assessment of Understanding (AoU): Volunteer demonstrates an understanding of this study and completes a questionnaire prior to first vaccination with verbal demonstration of understanding of questionnaire items that were answered incorrectly.
  2. 18 to 55 years old, inclusive, on day of enrollment.
  3. Confirmed infection as documented by medical records or confirmatory HIV testing at screening.
  4. On suppressive ART for at least 48 weeks prior to screening. ART is defined as a combination therapy regimen including at least 1 integrase inhibitor and 1 nucleoside reverse transcriptase inhibitor (such as Dovato™) or 2 nucleoside reverse transcriptase inhibitors plus integrase inhibitors. Changes in ARVs for reasons other than virologic failure (eg, tolerability, simplification, different formulation, drug-drug interaction profile) are allowed within 48 weeks prior to screening and up until 6 weeks prior to screening. A fully active alternative ARV regimen is available, in the opinion of the Investigator, in the event of discontinuation of the current ARV regimen with development of resistance.
  5. Plasma HIV RNA \< 50 copies/mL (or lower limit of quantitation [LLOQ]) for at least 48 weeks prior to enrollment. NOTE: At least one viral load measurement within 48 weeks prior to the screening visit and another viral load from the screening prior to enrollment visit must be available for review. Two "blips" (ie, plasma HIV-1 RNA > LLOQ and \< 400 copies/mL) are allowed if each blip is preceded and followed by values \< LLOQ and if the blip(s) occur(s) more than 24 weeks prior to enrollment.
  6. > 450 cells/mm3 and CD4+ cell % ≥ 15% obtained within 40 days prior to enrollment.
  7. Available for clinic follow-up through the last clinic visit, willing to undergo leukapheresis, and willing to be contacted 12 months after the last study-product administration.
  8. Agrees not to enroll in another study of an agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 807 PSRT are required prior to enrollment into HVTN 807.
  9. In good general health according to the clinical judgment of the site investigator.
  10. Physical examination and laboratory results without findings that would interfere with assessment of safety or reactogenicity in the clinical judgement of the site investigator.
  11. Total serum calcium of ≥ 8.5 mg/dL.
  12. (Hgb):

    • ≥ 10.0 g/dL for volunteers who were assigned female sex at birth (AFAB)
    • ≥ 11.0 g/dL for cisgender volunteers who were assigned male sex at birth (AMAB) and for transgender men who have been on hormone therapy for more than 6 consecutive months
    • ≥ 11.0 g/dL for transgender women who have been on hormone therapy for more than 6 consecutive months
    • For transgender volunteers who have been on hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth.
  13. (ANC) ≥ 750/mm3

    .

  14. ≥ 100,000/mm3

    .

  15. (ALT) \< 2.5 x (ULN) based on the institutional normal range and direct within the institutional range of normal.
  16. Estimated (eGFR) ≥ 60 mL/min/1.73m2 as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation.
  17. For Group 1 volunteers: must agree to consistently use condoms from study week 14 through until viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).
  18. For Group 1 volunteers

    • Persons of pregnancy potential

      • Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of enrollment.
      • Must agree to use effective means of from at least 21 days prior to enrollment until at least 8 weeks post last vaccination and viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).
    • Volunteers who are AFAB or intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through until viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).
  19. For Group 2 volunteers

    • Persons of pregnancy potential:

      • Must have a negative β-HCG pregnancy test (urine or serum) on day of enrollment.
      • Must agree to use effective means of contraception from at least 21 days prior to enrollment until 8 weeks after their last scheduled vaccination (study week 20).
    • Volunteers who are AFAB or intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.

Exclusion criteria

Exclusion Criteria:

  1. Current receipt of ART other than nucleoside reverse transcriptase inhibitor and integrase inhibitor.
  2. Receipt of long-acting ART within 3 months of enrollment.
  3. Documented history of resistance to any components of the current ARV regimen.
  4. Known resistance to 1 or more drugs in 2 or more ARV drug classes. NOTE: M184V/I is an exception and should not be considered when assessing this criterion. Prior resistance testing is not required.
  5. ART initiation during acute HIV-1 infection (defined as within 1 year of HIV-1 acquisition, if known).
  6. History of an HIV-associated (including Kaposi's sarcoma), and any type of lymphoma or virus-associated cancers.
  7. History of HIV-associated neurocognitive disease or progressive multifocal leukoencephalopathy.
  8. History of HIV-related illness under US Centers for Disease Control (CDC) Category C (except for recurrent pneumonia) within 10 years prior to screening, based on available medical history and assessed by the Investigator for clinical relevance. Anyone with a history of CD4 \< 200 cells/mm3 on one or more occasions, based on available medical history and assessed by the Investigator for clinical relevance. Documentation of every case with history of CD4 \< 200 cells/mm3 must be provided to the Sponsor and PSRT, who will determine eligibility on a case-by-case basis. NOTE: History of treated and resolved pulmonary tuberculosis (TB) will not be exclusionary.
  9. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery within 36 months prior to enrollment or for whom such therapies are expected in the subsequent 12 months. NOTE: Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) is not exclusionary.
  10. or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg), antibody without documented history of prior treatment and clearance, or hepatitis C virus RNA (HCV-RNA) in blood.
  11. Diagnosis of cirrhosis.
  12. Current untreated or incompletely treated active TB disease or untreated latent TB infection. NOTE: Individuals who are on treatment for latent TB with at least 4 weeks of treatment completed are not excluded.
  13. Volunteer who is breastfeeding or pregnant.
  14. (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by PSRT approval.
  15. Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis
  16. History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, including a previous diagnosis of any of the following:

    • Acute myocardial infarction
    • Acute coronary syndromes
    • Stable or unstable angina
    • Coronary or other arterial revascularization
    • Stroke
    • Peripheral arterial disease presumed to be of atherosclerotic origin
  17. Previous or current recipient of an HIV vaccine (previous placebo/control recipients are not excluded).
  18. Receipt of non-HIV experimental vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) emergency use listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.
  19. Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the site investigator, such as history of systemic (long-term use), anti-cancer or other immunosuppressive agents, interleukins, systemic interferons, systemic chemotherapy, or other medications considered significant by the investigator within the 24 weeks prior. Note: HIV is not exclusionary.
  20. Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.
  21. Previous receipt of any anti-HIV monoclonal antibody.
  22. Receipt of any of the following vaccines within 4 weeks prior to enrollment:

    • Live replicating vaccines
    • Any mRNA-based vaccine with FDA licensure, FDA EUA, or WHO EUL
    • ACAM2000 vaccine > 30 days prior with a vaccination scab still present.
  23. Receipt of any vaccines that are not covered in #22 above within 14 days prior to enrollment. Please note this includes replication incompetent vaccines such as the Jynneos vaccine for the prevention of mpox (formerly known as monkeypox) disease.
  24. Initiation of antigen-based immunotherapy (AIT) for allergies within the previous year (stable immunotherapy is not exclusionary); inclusion of participants who initiated immunotherapy within the previous year requires PSRT approval. Note: Any AIT should be scheduled at least 14 days prior to enrollment.
  25. Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of greater than 7 days (or unknown half-life) within the past year, PSRT approval is required for enrollment.
  26. History of serious reaction (eg, , anaphylaxis) to any vaccine or component of the study vaccine, including imidazoquinolone (eg, imiquimod).
  27. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
  28. Idiopathic urticaria within the past year.
  29. Bleeding disorder diagnosed by a clinician which would make study procedures a (eg, factor deficiency, coagulopathy, disorder requiring special precautions).
  30. Seizure disorder; febrile seizures as a child or seizures secondary to alcohol withdrawal more than 5 years ago are not exclusionary.
  31. Asplenia or functional asplenia.
  32. Active duty and reserve US military personnel.
  33. Any other chronic or condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of the study participant, including but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, persons with any suicide attempt within the past 1 year (if between 1 and 2 years, consult PSRT for approval), or cancer that, in the clinical judgement of the site investigator, has potential for recurrence (excluding basal cell carcinoma).
  34. A participant with a history of a potential immune-mediated medical condition (PIMMC), either active or remote. Specific examples are listed in Appendix I (AESI Index). Not exclusionary: 1) Remote history of Bell's palsy (> 2 years ago) not associated with other neurologic symptoms and 2) mild psoriasis that does not require ongoing systemic treatment.
  35. Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of intravenous drug use or substantial difficulty with previous blood draws.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Group 1 (ATI)

    Group 1 will receive 2 doses of the vaccine at Week 0 and 12. Group 1 will transition to Schedule 2 at the Week 14 visit. The Schedule 2 "ATI with Monitoring" phase can last for 24 weeks OR until any antiretroviral therapy (ART) re-initiation criteria are met, OR the ATI can continue longer with the approval of the Protocol Safety Review Team (PSRT) and the participant's primary HIV healthcare provider. Group 1 will transition to Schedule 3, the "Follow-up on ART restart" phase that lasts until study week 64, regardless of the point where it begins.

    Biological: 426c.Mod.Core-C4b · Other: Adjuvant 3M-052-AF+Alum

  • Experimental
    Group 2 (No ATI) Control

    Group 2 transitions from Schedule 1 into Schedule 4, "Follow-up on ART," at the Week 14 visit, and remains on Schedule 4 through study week 64.

    Biological: 426c.Mod.Core-C4b · Other: Adjuvant 3M-052-AF+Alum

Interventions

  • Biological426c.Mod.Core-C4b

    100 mcg and 300 mcg

  • OtherAdjuvant 3M-052-AF+Alum

    5 mcg

06

What researchers measure

Primary outcomes

  1. The number of participants local reactogenicity signs and symptoms

    Time frame: 14 days following each vaccination

  2. The number of participants systemic reactogenicity signs and symptoms

    Time frame: 14 days following each vaccination

  3. Number and description of serious adverse events (SAEs)

    adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

    Time frame: 12 months following any receipt of study product

  4. Number and description of medically attended adverse events (MAAEs)

    adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

    Time frame: 12 months following any receipt of study product

  5. Number and description of adverse events of special interest (AESIs)

    adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

    Time frame: 12 months following any receipt of study product

  6. Number and description of AEs leading to early participant withdrawal or permanent discontinuation and reason for withdrawal/discontinuation

    adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

    Time frame: 12 months following any receipt of study product

  7. Frequency of total Env-specific and CD4-bs-specific B cells, prior to ATI

    as assessed by flow cytometry at baseline and after each vaccination

    Time frame: At baseline (week 0) and after each vaccination

  8. Frequency of VRC01-class BCR sequences of isolated CD4-bs B cells, prior to ATI

    , as assessed by B-cell sorting and BCR sequencing

    Time frame: At baseline (week 0) and after each vaccination

  9. Frequency of Env-specific and CD4-bs-specific B cells

    as assessed by flow cytometry

    Time frame: After week 16

  10. Frequency of VRC01-class BCR sequences of isolated CD4-bs B cells

    as assessed by B-cell sorting and BCR sequencing

    Time frame: After week 16

Secondary outcomes

  1. Compare Env sequences during ATI in Group 1 participants that initiated the development of VRC01 antibodies and those that did not

    Time frame: Study duration or 12 months following any receipt of study product

  2. Magnitude of Binding of selected recEnvs from Group 1 participants that initiated the development of VRC01-class antibodies to VRC01-class precursor and intermediate antibodies

    Time frame: Study duration or 12 months following any receipt of study product

  3. Magnitude of Binding of selected recEnvs from Group 1 participants that initiated the development of VRC01-class antibodies to B cells expressing VRC01-class BCRs.

    Time frame: Study duration or 12 months following any receipt of study product

Other outcomes

  1. Magntidue of binding and neutralizing activity of any VRC01-class antibodies isolated during the study

    Time frame: Study duration or 12 months following any receipt of study product

  2. Frequency of occurrence of similarities s in viral sequences of Group 2 participants (if any viruses emerge on study) with Group 1 participants

    Time frame: Study duration or 12 months following any receipt of study product

  3. Magnitude of participant and potential participant motivations, perceptions and tolerance for ATIs, for prolonged viremia, and for trial requirements (eg, ART switches, barrier protection for all sexual activity)

    Time frame: Study duration or 12 months following any receipt of study product

  4. Magnitude of social benefits (eg, altruism) and negative social impacts, including but not limited to anxiety regarding being off ART and becoming viremic again and fear of inadvertent HIV transmission to partners

    Time frame: Study duration or 12 months following any receipt of study product

  5. Magnitude of participant and potential participant decision-making quality, including perception of being informed, clarity and support in decision making, and satisfaction with their choice regarding participation.

    Time frame: Study duration or 12 months following any receipt of study product

  6. Response rate of immunogenicity of each vaccine regimen, additional virologic and immunogenicity assays may be performed in a subset of participants, including on samples from other timepoints

    Time frame: Study duration or 12 months following any receipt of study product

  7. Conduct analysis related to furthering the understanding of HIV, immunology, vaccines, and clinical trial conduct

    Time frame: Study duration or 12 months following any receipt of study product

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2026, 33 months.

Of 91 non-industry phase 1 interventional studies under HIV Infections, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 33 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 23, 2023
StartActual
Jan 3, 2024
Primary completionActual
Oct 12, 2026
CompletionActual
Oct 12, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Sites
5 sites added, 6 sites removed
Show 5 added (5 United States)
  • Alabama CRS (Site # 31788) · Birmingham, United States
  • The Ponce de Leon Center CRS (Site # 5802) · Atlanta, United States
  • BIDMC VCRS (Site # 32077) · Boston, United States
  • Columbia P&S CRS (Site # 30329) · New York, United States
  • University of Pittsburg CRS (Site # 1001) · Pittsburgh, United States
Show 6 removed
  • Birmingham · Birmingham, United States
  • Atlanta- Ponce · Atlanta, United States
  • BIDMC · Boston, United States
  • Columbia P&S CRS Site#30329 · New York, United States
  • University of Pittsburg · Pittsburgh, United States
  • Fred Hutchinson Cancer Research Center · Seattle, United States
Nov 6, 2026
Primary completion
Oct 27, 2026→Oct 12, 2026 (actual)
Nov 6, 2026
Study completion
Oct 27, 2026→Oct 12, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    5 sites added, 6 sites removed
    Show 5 added (5 United States)
    • Alabama CRS (Site # 31788) · Birmingham, United States
    • The Ponce de Leon Center CRS (Site # 5802) · Atlanta, United States
    • BIDMC VCRS (Site # 32077) · Boston, United States
    • Columbia P&S CRS (Site # 30329) · New York, United States
    • University of Pittsburg CRS (Site # 1001) · Pittsburgh, United States
    Show 6 removed
    • Birmingham · Birmingham, United States
    • Atlanta- Ponce · Atlanta, United States
    • BIDMC · Boston, United States
    • Columbia P&S CRS Site#30329 · New York, United States
    • University of Pittsburg · Pittsburgh, United States
    • Fred Hutchinson Cancer Research Center · Seattle, United States
    Primary completion Oct 27, 2026→Oct 12, 2026 (now actual)
    Study completion Oct 27, 2026→Oct 12, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06006546
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Jan 3, 2024
Primary completion
Oct 12, 2026
Completion
Oct 12, 2026
Last update
Nov 6, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion